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In 2009, in the Active Bacterial Core surveillance sites, penicillin
was not commonly used to treat meningococcal disease. This is
likely because of inconsistent availability of antimicrobial sus-
ceptibility testing and ease of use of third-generation cephalo-
sporins. Consideration of current practices may inform future
meningococcal disease management guidelines.
Keywords. antimicrobial resistance; meningitis; meningo-
coccal disease; Neisseria meningitidis.
Meningococcal disease is a severe infection caused by the bac-
terium Neisseria meningitidis, which causes death or permanent
disability in 1 of every 4 patients. Penicillin has historically been
used for treatment of laboratory-confirmed meningococcal in-
fections, and it remains a treatment of choice in both adult and
pediatric treatment guidelines [1]. Vancomycin plus a broad-
spectrum cephalosporin is recommended for empiric treatment
of bacterial meningitis; when microbiologic diagnosis of Nmen-
ingitidis is confirmed, penicillin is recommended, preferably
with evidence of full susceptibility on antimicrobial susceptibil-
ity testing (AST) [2, 3].
We report the findings of an expanded medical record review
project conducted in the Active Bacterial Core surveillance
(ABCs) sites (1) to estimate the frequency of penicillin use to
treat meningococcal disease and (2) to determine availability
of AST and its use in guiding treatment, as recommended by
current adult and pediatric guidelines. Understanding current
practices of healthcare providers in prescribing penicillin for
treatment of meningococcal disease and the availability of
AST are important to characterize the clinical and public health
significance of any increased penicillin nonsusceptibility in
N meningitidis, and these steps may help inform treatment
recommendations.
METHODS
A retrospective expanded medical record review was conducted
for N meningitidis cases reported to ABCs in 2009. Active Bac-
terial Core surveillance is an active, population- and laboratory-
based surveillance system that is supported by the Centers for
Disease Control and Prevention (CDC) as part of its Emerging
Infections Program Network [4]. The ABCs sites that partici-
pated in the expanded medical record review included Califor-
nia (3 San Francisco Bay area counties), Colorado (5 Denver
area counties), Connecticut, Georgia’s Atlanta Metropolitan
Statistical Area, Maryland, Minnesota, New Mexico, Oregon,
New York (15 Rochester and Albany area counties), and Ten-
nessee (11 urban counties). The population under surveillance
in these sites in 2009 was 36 748 349, representing 12.0% of the
US population.
A case was defined as isolation of N meningitidis from a nor-
mally sterile site (eg, blood or cerebrospinal fluid) in a resident
of a surveillance area. Syndrome was defined as the clinical di-
agnosis reported in the medical record (meningitis, pneumonia,
or bacteremia).
The standard ABCs case-report form collects demographics,
clinical syndrome, underlying conditions, serogroup, and out-
come data abstracted from medical records. A 1-page, expanded
form was used to collect the following: all antibiotics prescribed
within the first 10 days of hospitalization; clinical tests and their
results; AST availability, methods, and results; intensive care
unit (ICU) admission; consultation with an infectious disease
specialist; intubation; and concurrent infections.
Antimicrobial susceptibility testing was performed at the
CDC using Etest antibiotic gradient strips. Mueller Hinton
agar with 5% sheep blood (BD, Franklin Lakes, NJ) was used.
Inoculum plating and strip application were carried out in
accordance with the manufacturer’s instruction, using an auto-
matic turntable and a multiple strip dispenser (AB Biodisk).
Antibiotic concentrations ranged from 0.016 to 256 µg/mL for
penicillin. Currently, there are no standards for AST of menin-
gococci approved by the Clinical Laboratory Standards Institute
(CLSI). Etest minimum inhibitory concentrations (MICs) were
interpreted by rounding up the half-dilution (if applicable) to
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the next standard broth microdilution 2-fold dilution before ap-
plying CLSI MIC breakpoints, as recommended by the manufac-
turer [5].
Statistical analysis was performed in SAS version 9.3 (SAS
Institute, Inc., Cary, NC). Differences between proportions
were tested using Pearson’s χ2 test or Fisher’s exact test. Differ-
ences between means were tested using Student’s t test.
RESULTS
In 2009, 123 cases of N meningitidis were reported by partici-
pating ABCs sites; of these, 122 had a medical record available
for review. Cases had a median age of 24.5 years (range, 42
days–95 years), 64 cases (53%) were female, 83 cases (68%)
were white, and 10 cases (8%) were Hispanic. No underlying
conditions were present in 54 cases (44%). The most frequent
underlying conditions or risk factors reported in adults were
current smoking (n = 16, 21%) and diabetes (n = 14, 18%).
The most frequently reported underlying conditions in pediat-
ric cases were obesity (n = 2, 5%) and prematurity (n = 2, 5%).
Neisseria meningitidis was isolated from blood in 96 cases (79%)
and from cerebrospinal fluid in 34 cases (28%). Meningitis was the
most common clinical syndrome (n = 52, 43%), followed by bac-
teremia (n = 36, 30%) and bacteremic pneumonia (n = 18, 15%).
An infectious disease specialist was consulted in 84 cases
(69%), but there was no significant difference in treatment
based on this consultation. Of 57 cases (47%) admitted to the
ICU, 19 (33%) were intubated. Eight (7%) patients died.
Most cases were treated with a broad-spectrum cephalospo-
rin (n = 104, 85%) and/or vancomycin (n = 55, 45%). Only 14
cases (11%) were treated with penicillin at any time during
their illness, and no cases were treated exclusively with penicil-
lin. Of the 14 cases that received penicillin, 3 were pediatric
cases (ages 3 months, 3 months, and 17 years) and 11 were
adults between the ages of 18 and 64. None of the penicillin
recipients died. A comparison of characteristics between
penicillin recipients and nonrecipients can be seen in Table 1.
Antimicrobial susceptibility testing results were available in
the medical record for 30 of the 122 cases. The reported AST
method used was disk diffusion in 9 cases (30%), Etest in 1
case (1%), broth microdilution in 1 case (1%), and unspecified
in 19 cases (63%). The median interval from the date of first
positive culture to the AST report date was 1 day (range, 0–24
days). Of the 30 cases with AST, 19 had AST for penicillin.
Five of these 19 (26%) were treated with penicillin, both before
and after AST results. Penicillin recipients were more likely to
have AST than nonrecipients (P = .04) (Table 1). All 3 of the
pediatric cases that received penicillin also had AST. The AST
results reported in the medical records included 1 case each of
penicillin resistance, penicillin intermediate susceptibility,
ciprofloxacin resistance, and rifampin resistance and 3 cases
of sulfamethoxazole/trimethoprim resistance. The testing
method was disk diffusion in the case of rifampin resistance
and the 3 cases of sulfamethoxazole/trimethoprim resistance.
The testing method was unknown in the other cases of resis-
tance and intermediate susceptibility.
Of the 123 cases reported to ABCs in 2009, 101 had AST per-
formed at the CDC. Thirty-seven cases (37%) showed interme-
diate penicillin susceptibility, and 1 case showed penicillin
resistance. Of these 37 intermediate penicillin-susceptible cases,
2 were treated with penicillin. All of the 101 isolates tested at the
CDC were susceptible to ceftriaxone, ciprofloxacin, rifampin,
and azithromycin.
The penicillin-resistant case identified in the medical record
review did not have an isolate available for testing at the CDC.
The case of intermediate penicillin susceptibility identified in the
medical record was also identified as a case of intermediate peni-
cillin susceptibility at the CDC. None of the cases of intermediate
penicillin susceptibility or resistance identified at the CDC had
AST results in their medical records. The case of ciprofloxacin re-
sistance identified in the medical record review was tested at the
CDC and was found to be susceptible to ciprofloxacin.
DISCUSSION
Our findings suggest that penicillin is not being used frequently
to treat meningococcal disease with only 11% of cases in 2009 re-
ceiving penicillin in the ABCs sites. Antimicrobial susceptibility
testing is not widely available, but it is noteworthy that AST
was performed more frequently in penicillin recipients versus
nonrecipients, and a variety of AST methods were used in the
clinical laboratories. Our findings are consistent with results
from a recent survey of infectious disease physicians on reported
Table 1. Characteristics of Cases of Neisseria meningitidis, Active
Bacterial Core Surveillance, 2009
Penicillin Given
P ValueYes (n = 14) No (n = 108)
Age in years, mean 31.1 32.3 .89
Age group, n (%)
Pediatric 3 (21.4) 41 (38.0) —
Adult 11 (78.6) 67 (62.0) .38
Male, n (%) 10 (71.4) 48 (44.4) .09
Syndrome, n (%)
Bacteremia 3 (21.4) 33 (33.0) —
Bacteremic pneumonia 0 18 (18.0) .54
Meningitis 8 (57.4) 44 (44.0) .51
Other 3 (21.4) 5 (5.0) .06
AST performed, n (%) 7 (50.0) 23 (22.12) .04
ICU admission, n (%) 8 (57.1) 49 (46.2) .56
Intubation, n (%) 4 (30.8) 17 (19.3) .46
ID consult, n (%) 13 (92.9) 71 (66.4) .06
Died, n (%) 0 8 (7.4) .59
The bold value indicates a statistically significant difference between penicillin recipients and
non-recipients.
Abbreviations: AST, antimicrobial susceptibility testing; ICU, intensive care unit; ID,
infectious diseases.
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practice for the management of meningococcal disease, which
found that US physicians frequently continue treatment with
third-generation cephalosporins rather than switching to penicil-
lin after microbiological confirmation of Nmeningitidis, irrespec-
tive of the availability of AST [6]. The most common reasons for
not switching included concerns about CSF penetration, a desire
not to change working treatments, and the cost effectiveness and
ease of use of cephalosporins. Some physicians did report contin-
ued treatment with cephalosporins as a result of concerns about
antibiotic resistance or the lack of availability of AST.
Cases of invasive meningococcal disease caused by strains
with reduced susceptibility to penicillin were first reported in
the 1980s in United Kingdom, Spain, and South Africa but
are now identified worldwide [7]. The first reported cases of dis-
ease caused by meningococci with reduced susceptibility to
penicillin in the United States were in the early 1990s [7]. Stud-
ies evaluating whether meningococcal disease with reduced sus-
ceptibility to penicillin results in higher morbidity and
mortality are inconclusive, but recent studies show no associa-
tion with either intermediate penicillin susceptibility or penicil-
lin resistance and death [7–9].
Although the sample size was small, most cases included in
this expanded medical record review were treated with a broad-
spectrum cephalosporin and/or vancomycin, and no cases were
treated exclusively with penicillin. Information on antibiotic
start and stop dates and administration times were missing or
inconsistently documented, making it difficult to determine
whether AST or microbiological diagnoses were influencing
prescribing decisions. All available isolates from cases included
in this review were tested at the CDC and were susceptible to
ceftriaxone, ciprofloxacin, rifampin, and azithromycin. The
low levels of resistance to nonpenicillin antibiotics and the
use of broad-spectrum antibiotics in most of the cases would
limit any potential impact of intermediate penicillin susceptibil-
ity on clinical outcomes. As a result of these findings and the
relatively low levels of penicillin-reduced susceptibility, data
were only collected for 2009, which may limit the relevance of
the data because current practices may have changed.
CONCLUSIONS
In summary, in 2009 penicillin was not commonly used for
treatment of meningococcal disease in the United States
There are likely several reasons for this, including inconsistent
availability of AST, ease of use of third-generation cephalospo-
rins, and reduced susceptibility to ceftriaxone being more rare
than reduced susceptibility to penicillin. Consideration of cur-
rent practices may inform future meningococcal disease man-
agement guidelines.
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